Recent News

• 06.12.2025 - R. Keith Woods
• 06.12.2025 - R. Keith Woods
• 06.10.2025 - X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
• 06.10.2025 - X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
• 06.02.2025 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.02.2025 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.14.2025 - X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
• 05.14.2025 - X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
• 05.01.2025 - X4 Pharmaceuticals First Quarter 2025 Financial Results
• 05.01.2025 - X4 Pharmaceuticals First Quarter 2025 Financial Results

Recent Filings

• 06.11.2025 - 8-K Current report
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2025 - 4/A Statement of changes in beneficial ownership of securities
• 06.03.2025 - 3 Initial statement of beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities